← All companies ← ASML Manual ASR → ← ASMB Pharmaceuticals ATAI →
ASND, Ascendis Pharma A/S Ordinary Share
A pharmaceutical business, where patents grant a temporary monopoly the pipeline must keep refilling.
The business
What it sells, where the money comes from, the kind of company it is.
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- Situation
- Unprofitable. No sustained operating profit across the record; an earnings multiple has nothing to rest on. What the record does show is revenue, the gross-margin trajectory, and the burn against the cash on hand. Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
- What moves the needle
- Operating margin has run around −1583% through the cycle on a 87% gross margin, the operating line in the red even at its best — so the lever is whether the spending below the gross line can come down enough to clear a profit: revenue growth against the cost curve, and the cash runway until it does. Inventory runs near 49% of sales, so how fast it turns back into cash — and the risk of writing it down when demand softens — sits alongside the margin. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on customer concentration, set against the numbers in what the filing emphasizes, below.
- Is it a good business?
- Return on capital has rarely cleared the cost of capital (median −172%, above 15% in 0 of 6 years). Owner earnings, the cash-based check, have been thin too. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.
Every line is arithmetic on the company's filings, shown in full in the sections below.
Where the money comes from
read the 20-F →United States is 76% of revenue, so this is largely a single-region business.
- United States76%€546M
- Europe17%€121M
- Rest of world7%€53M
- Denmark2%€13M
From the segment footnote of the company's own 20-F. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.
The record
Ten years of arithmetic, read across the cycle.
The record, 2016–2025
realized figures from each filing · older years to the left| 2016’16 | 2017’17 | 2018’18 | 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | TTMTTMDec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| €5M | €2M | €11M | €13M | €7M | €8M | €51M | €267M | €364M | €720M | €720M | RevenueRevenue |
| — | — | — | — | — | 55% | 76% | 83% | — | — | — | Gross marginGross mgn |
| (€73M) | (€112M) | (€155M) | (€227M) | (€331M) | (€452M) | (€562M) | (€456M) | (€279M) | (€136M) | (€136M) | Operating incomeOp. inc. |
| n/m | n/m | n/m | n/m | n/m | n/m | n/m | −170.8% | −76.7% | −18.9% | −18.9% | Operating marginOp. mgn |
| (€69M) | (€124M) | (€130M) | (€218M) | (€419M) | (€384M) | (€583M) | (€481M) | (€378M) | (€228M) | (€228M) | Net incomeNet inc. |
| Cash flow & returns | |||||||||||
| (€60M) | (€95M) | (€139M) | (€176M) | (€272M) | (€418M) | (€496M) | (€467M) | (€306M) | €54M | €54M | Operating cash flowOp. cash |
| €677K | €734K | €880K | €7M | €9M | €15M | €18M | €18M | €17M | €17M | €17M | DepreciationDeprec. |
| €8M | €28M | (€10M) | €35M | €138M | (€49M) | €70M | (€4M) | €55M | €265M | €265M | Working capital & otherWC & other |
| €672K | €941K | €3M | €5M | €20M | €24M | €14M | €2M | — | — | €945K | CapexCapex |
| 14.6% | 61.5% | 25.0% | 38.6% | 285.6% | 304.8% | 28.3% | 0.9% | — | — | 0.1% | Capex / revenueCapex/rev |
| (€61M) | (€96M) | (€140M) | (€181M) | (€281M) | (€433M) | (€510M) | (€470M) | — | — | €53M | Owner earningsOwner earn. |
| n/m | n/m | n/m | n/m | n/m | n/m | −997.0% | −176.1% | — | — | 7.4% | Owner earnings marginOE mgn |
| (€61M) | (€96M) | (€141M) | (€181M) | (€291M) | (€441M) | (€510M) | (€470M) | — | — | €53M | Free cash flowFCF |
| n/m | n/m | n/m | n/m | n/m | n/m | −997.0% | −176.1% | — | — | 7.4% | Free cash flow marginFCF mgn |
| — | — | — | — | — | €22M | €105M | €0 | €0 | €17M | — | BuybacksBuybacks |
| — | — | -5588% | — | -103% | -66% | -204% | — | -139% | -301% | -301% | ROICROIC |
| -39% | -66% | -46% | -37% | -50% | -43% | -221% | — | — | — | — | Return on equityROE |
| −39% | −66% | −46% | −37% | −50% | −43% | −221% | — | — | — | — | Retained to equityRetained/eq |
| Balance sheet | |||||||||||
| €180M | €195M | €278M | €598M | €585M | €446M | €445M | €392M | €560M | €616M | €616M | Cash & investmentsCash+inv |
| €287K | €188K | €6K | €804K | €387K | €2M | €12M | €12M | €166M | €141M | €141M | ReceivablesReceiv. |
| — | — | — | — | €0 | €75M | €131M | €131M | €296M | €302M | €302M | InventoryInvent. |
| €13M | €24M | €31M | — | — | — | — | — | — | — | €31M | Accounts payablePayables |
| (€13M) | (€24M) | (€31M) | €804K | €387K | €78M | €143M | €143M | €462M | €443M | €412M | Operating working capitalOper. WC |
| €184M | €205M | €293M | €611M | €740M | €806M | €923M | €923M | €1.1B | €1.1B | €1.1B | Current assetsCur. assets |
| €13M | €24M | €39M | €48M | €53M | €100M | €171M | €717M | €908M | €1.1B | €1.1B | Current liabilitiesCur. liab. |
| 13.7× | 8.6× | 7.5× | 12.7× | 14.0× | 8.0× | 5.4× | 1.3× | 1.2× | 1.0× | 1.0× | Current ratioCurr. ratio |
| €3M | €3M | €3M | €3M | €3M | — | — | — | — | — | €3M | GoodwillGoodwill |
| €190M | €211M | €319M | €677M | €980M | €1.1B | €1.1B | €1.1B | €1.2B | €1.3B | €1.3B | Total assetsAssets |
| — | — | — | — | — | €105M | €399M | €495M | €823M | €815M | €815M | Total debtDebt |
| — | — | — | — | — | (€341M) | (€46M) | €102M | €264M | €199M | €199M | Net debt / (cash)Net debt |
| -23.4× | -8.1× | -1218.6× | -185.7× | -4.1× | -115.5× | -11.1× | -10.3× | -2.8× | -0.7× | -0.7× | Interest coverageInt. cov. |
| €177M | €187M | €280M | €597M | €839M | €884M | €263M | (€146M) | (€106M) | (€163M) | (€163M) | Shareholders’ equityEquity |
| Per share | |||||||||||
| 26.6M | 33.6M | 41.1M | 46.5M | 50.6M | 54.8M | 56.1M | 56.3M | 57.9M | 60.6M | 56.9M | Shares out (diluted)Shares |
| €0.17 | €0.05 | €0.26 | €0.29 | €0.14 | €0.14 | €0.91 | €4.74 | €6.28 | €11.88 | €12.66 | Revenue / shareRev/sh |
| €-2.58 | €-3.68 | €-3.17 | €-4.69 | €-8.28 | €-7.00 | €-10.40 | €-8.55 | €-6.53 | €-3.76 | €-4.01 | EPS (diluted)EPS |
| €-2.29 | €-2.85 | €-3.40 | €-3.89 | €-5.55 | €-7.90 | €-9.10 | €-8.35 | — | — | €0.93 | Owner earnings / shareOE/sh |
| €-2.29 | €-2.86 | €-3.44 | €-3.89 | €-5.76 | €-8.06 | €-9.10 | €-8.35 | — | — | €0.93 | Free cash flow / shareFCF/sh |
| €0.03 | €0.03 | €0.06 | €0.11 | €0.39 | €0.43 | €0.26 | €0.04 | — | — | €0.02 | Cap. spending / shareCapex/sh |
| €6.65 | €5.57 | €6.82 | €12.84 | €16.57 | €16.13 | €4.70 | €-2.59 | €-1.83 | €-2.69 | €-2.86 | Book value / shareBVPS |
| 9-yr | 5-yr | |
|---|---|---|
| Revenue / share | +60.0%/yr | +144.0%/yr |
| Capital spending / share | +8.0%/yr (7-yr) | −7.6%/yr |
The record, charted
FY2016–2025Each measure over its full record; the current point and the worst year marked.
Owner earnings vs. net income
Owner earningsNet incomeThe accountant's number, and the cash an owner can take; the gap is the tell.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2023 the business turned a €481M loss into (€470M) of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.
| FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|
| Reported net income | (€481M) | (€583M) | (€384M) | (€419M) | (€218M) |
| Depreciation & amortizationnon-cash charge added back | +€18M | +€18M | +€15M | +€9M | +€7M |
| Working capital & othertiming of cash in and out, other non-cash items | −€4M | +€70M | −€49M | +€138M | +€35M |
| Cash from operations | (€467M) | (€496M) | (€418M) | (€272M) | (€176M) |
| Maintenance capital expenditurethe spending needed just to hold position and volume | −€2M | −€14M | −€15M | −€9M | −€5M |
| Owner earnings | (€470M) | (€510M) | (€433M) | (€281M) | (€181M) |
| Growth capital expenditurediscretionary; spent to get bigger, not to stand still | — | — | −€9M | −€10M | — |
| Free cash flow | (€470M) | (€510M) | (€441M) | (€291M) | (€181M) |
| Owner-earnings marginowner earnings ÷ revenue | -176% | -997% | -5562% | -4041% | -1354% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
Will it survive?
- Can it pay its interest? -0.7×Does not cover its interestOperating income (€136M) ÷ interest expense €207M
What this means
A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.
- Net debt against an operating lossCash €616M − debt €815M
What this means
Netting €616M of cash and short-term investments against €815M of debt leaves €199M owed, with no operating profit this year to measure it against — understand that combination before anything else about the company. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Long (60+ days)DSO 72 + DIO 1160 − DPO 119 days
What this means
Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.
Is it a good business?
- Below average through the cycle6-yr median, range -5588%–-66%; -301% latest = NOPAT (€108M) ÷ invested capital €36MIndustry peers: median 6%
What this means
The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 6 years (it ran -301% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.
- Positive this year, negative across the cyclelatest €53M = operating cash €54M − maintenance capex €945K (positive this year), after an earlier loss stretch (8-yr median -1354%)Industry peers: median 15%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 7% of revenue this year, a -1354% median across 8 years.
- Loss, but cash-generativeNet income (€228M) · cash from operations €54M
What this means
The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did.
How is the cash used?
- Reinvests most of itDividends + buybacks €17M ÷ Owner Earnings €53M
What this means
Of €53M Owner Earnings, €17M (33%) went back to shareholders, €0 dividends, €17M buybacks. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.
- Investing or harvesting? 0.05×HarvestingCapex €945K ÷ depreciation €17M
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
Graham’s defensive tests · 0 of 4 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size —Revenue ≥ $2B (a dollar floor) · €720M
What this means
Big enough to weather a storm. Graham's floor is a dollar figure — about $2B of revenue as a conservative modern stand-in. This company reports in its home currency and we carry no exchange rate, so we show the figure and leave the size bar for you to apply rather than convert it with a number we don't have.
- Strong liquidity MissCurrent ratio ≥ 2× · 1.04×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt MissDebt ≤ working capital · €815M vs €40M WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Earnings stability MissA profit every year (10-yr record) · 10 loss years
What this means
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record MissUninterrupted dividends · none paid
What this means
An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.
- Earnings growth —Earnings +33% over the record · —
What this means
Earnings were negative early in the record, a growth rate isn't meaningful.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are €-5.85/share (latest year €-3.68), the averaged base the calculator's gate runs on, and book value is €-2.63/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2016–2025
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 0 of 10
What this means
Lost money in 10 year(s), look at what happened there before trusting the average.
- Return on capital ≥ 15% 0 of 4 yrs
What this means
A moat shows up as a high return on invested capital that holds year after year, not one good vintage.
- Operating margin −3445% → −89% (3-yr avg ends)
In the filing’s words The margin widened even though the filing names price competition — the gain came from volume or cost, not pricing power. Read where.
What this means
Through the cycle the operating margin widened — about −3445% early to −89% lately, median −1583% — pricing power intact or improving.
- Reinvestment, incremental ROIC returns capital
What this means
The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.
- Worst year 2017 · −7290.3% op. margin
What this means
Operations went underwater in 2017, understand why before trusting the good years.
Does AI threaten the moat?
Low contestabilityThe moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.
The filing raises AI among its risks, but in other terms (security, regulation, energy or the like), not as a competitor to its product; it frames AI mainly as a capability.
AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat, and the company is using it that way.
Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.
All figures as filed; the source filing is linked above.
Current Position
as of fiscal year-end, Dec 31, 2025Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments€616M
- Receivables€141M
- Inventory€302M
- Other current assets€50M
- Debt due within a year€429M
- Accounts payable€31M
- Other current liabilities€609M
From the company's latest filing.
Peers, Pharmaceuticals
The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.
| Company | Revenue | Gross margin | Op. margin | ROIC | Owner earn. margin |
|---|---|---|---|---|---|
| CORTCorcept Therapeutics Incorporated | $761M | 98% | 30.6% | 25% | 34% |
| EBSEmergent BioSolutions Inc. | $743M | 58% | 12.5% | 6% | 8% |
| PCRXPacira BioSciences | $726M | 73% | 3.7% | 2% | 16% |
| ASNDAscendis Pharma A/S Ordinary Share | €720M | 76% | -1522.9% | -172% | -1338% |
| AMPHAmphastar Pharmaceuticals Inc. | $720M | 43% | 11.0% | 9% | 15% |
| SUPNSupernus Pharmaceuticals Inc. | $719M | 90% | 20.0% | 11% | 26% |
| KNSAKiniksa Pharmaceuticals International, PLC | $678M | 88% | -9.3% | -6% | 5% |
| RAREUltragenyx | $673M | 100% | -154.9% | -92% | -113% |
| Group median | — | 82% | 7.4% | 4% | 11% |
The price
What a price has to assume.
What the price implies
reverse-DCFEnter the US price, in dollars: the NYSE/Nasdaq quote you hold. Per the filing's own cover, “American Depositary Shares , each representing one ordinary”; Ascendis Pharma A/S Ordinary Share reports in EUR, so every figure in this tool is stated per ADS and translated at EUR 1 = $1.145 (2026-07-17, reference rate) so your dollar quote reconciles exactly. The record tables elsewhere on this page remain as filed, in EUR.
Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Ascendis Pharma A/S Ordinary Share has delivered.
—
9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.
Enter a price above to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.
Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.
Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.
Owner earnings $61M on 62M shares outstanding, per the 20-F cover, as of 2025-12-31; net debt $227M. The base is the latest year by default; Normalize values it on the through-cycle median owner-earnings margin (to avoid paying on a peak year). Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.
Manual order: ← ASML its page in the Manual ASR →
Industry order: ← ASMB the Pharmaceuticals chapter ATAI →